Literature DB >> 3372998

Murine graft vs host disease. A model for study of mechanisms that generate autoantibodies to ribonucleoproteins.

C Gelpi1, J L Rodriguez-Sanchez, M A Martinez, J Craft, J A Hardin.   

Abstract

We established chronic graft vs host disease in (BALB/c x A/J) F1 mice with the injection of lymphoid cells from the parental A/J strain. These animals developed glomerulonephritis, forefoot edema, alopecia, splenomegaly, and lymphadenopathy to various degrees, and all developed antinuclear antibodies. To determine whether these antibodies were directed against the small nuclear ribonucleoprotein (snRNP) particles that are characteristic targets for autoimmune responses in human rheumatic diseases, sera were studied in the 32P immunoprecipitation and immunoblotting assays. Among 20 mice, antibodies to snRNP developed in 10. These antibodies usually reached maximal levels about 4 wk after induction of graft vs host disease and generally fell thereafter. However, two mice developed antibodies to snRNP between the 10th and 20th wk of follow-up. Sera from six mice strongly recognized the U1 snRNP and an additional serum strongly bound both the U1 and U3 particles. Several sera contained lower levels of antibodies specific for the U3 and possibly pre-U2 snRNP particles. In immunoblots, sera that immunoprecipitated the U1 snRNP bound epitopes located on its 70,000 Da, A, B'/B, and/or C polypeptides. Sera that immunoprecipitated the U3 snRNP recognized a 34,000-Da polypeptide. These polypeptides are known to bear the autoantigenic epitopes that are recognized by human sera containing anti-U1 RNP and anti-U3 RNP autoantibodies. We conclude that chronic graft vs host disease in mice provides a model for the study of the autoimmune responses that characterize human diseases such as mixed connective tissue disease, scleroderma, and SLE.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3372998

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Animal models for scleroderma: an update.

Authors:  Yan Zhang; Anita C Gilliam
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

Review 2.  snRNPs and scRNPs as autoantigens: clues to the etiology of the connective tissue diseases.

Authors:  J Craft; M Mamula; Y Ohosone; G Boire; H Gold; J Hardin
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

3.  Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.

Authors:  Gerson Dierley Keppeke; Minoru Satoh; Maria Lucia Gomes Ferraz; Edward K L Chan; Luís Eduardo C Andrade
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

4.  T lymphocyte activation in systemic lupus erythematosus analysed by proliferative response to nucleoplasmic proteins on nitrocellulose immunoblots.

Authors:  B N Pham; L Prin; D Gosset; P Y Hatron; B Devulder; A Capron; J P Dessaint
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

Review 5.  Advances in lupus stemming from the parent-into-F1 model.

Authors:  Charles S Via
Journal:  Trends Immunol       Date:  2010-03-31       Impact factor: 16.687

6.  Anti-fibrillarin autoantibodies in mercury-treated mice.

Authors:  P Hultman; S Eneström; K M Pollard; E M Tan
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

7.  Fine specificities of anti-nuclear antibodies in murine models of graft-versus-host disease.

Authors:  A P van Dam; J F Meilof; H G van den Brink; R J Smeenk
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

8.  Cloned human snRNP proteins B and B' differ only in their carboxy-terminal part.

Authors:  A van Dam; I Winkel; J Zijlstra-Baalbergen; R Smeenk; H T Cuypers
Journal:  EMBO J       Date:  1989-12-01       Impact factor: 11.598

9.  (SWR x SJL)F1 mice: a new model of lupus-like disease.

Authors:  S Vidal; C Gelpí; J L Rodríguez-Sánchez
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.